Quinine (cinchonan-9-ol, 6'-methoxy-, (8alpha, 9R)-) and its salts
New Zealand Cosmetic Products Group Standard Schedule 5, reference 21.
Regulatory decision and full conditions
- Status
- Restricted
- Legal role
- Binding rule
- Regulatory summary
- New Zealand Cosmetic Products Group Standard Schedule 5, reference 21.
- Conditions and restrictions
- Product scope: (a) Hair rinse-off products (b) Hair leave-on products · Maximum concentration: (a) 0.5% calculated as quinine base (b) 0.2% calculated as quinine base
Substance identity
- Official source name
- Quinine (cinchonan-9-ol, 6'-methoxy-, (8alpha, 9R)-) and its salts
- CAS
- 130-95-0
- EC
- 205-003-2
- Identity mapping
- cas_number
- Linked ingredient
- QUININE
Linked CosIng identity data
Names and aliases
CosIng description: Cinchonan-9-ol, 6'-methoxy-, (8.alpha., 9R)-
EU inventory restriction note: III/21
Recorded cosmetic function: DENATURANT, FRAGRANCE, HAIR CONDITIONING
Function pages:DENATURANT, FRAGRANCE, HAIR CONDITIONING
View the complete ingredient profileCross-market snapshot for this identity
Exact linked records currently present in this site. An absent market means no imported exact match, not permission to use the substance.
European Union
1 linked record · 1 with specific conditions
Open supporting recordGreat Britain
1 linked record · 1 with specific conditions
Open supporting recordNew Zealand
Current record1 linked record · 1 with specific conditions
Open supporting recordASEAN
1 linked record · 1 with specific conditions
Open supporting recordSouth Korea
1 linked record · 1 with specific conditions
Open supporting recordAustralia
1 linked record · 1 with specific conditions
Open supporting recordIndia
1 linked record · 1 with specific conditions
Open supporting recordSaudi Arabia
1 linked record
Open supporting recordVerified chemistry for CAS 130-95-0
Quinine
Quinine is a cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy. It has a role as a non-narcotic analgesic, an antimalarial and a muscle relaxant. It is a conjugate base of a quinine(1+). It derives from a hydride of an (8S)-cinchonan. — ChEBI
- IUPAC name
- (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
- Molecular formula
- C20H24N2O2
- Molecular weight
- 324.4 g/mol
- Exact mass
- 324.183778013 Da
- Monoisotopic mass
- 324.183778013 Da
- XLogP3
- 2.9
- Topological polar surface area
- 45.6 Ų
- Molecular complexity
- 457.0
- Formal charge
- 0
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 4
- Rotatable bonds
- 4
- Heavy atoms
- 24
- Covalent units
- 1
Names and synonyms reported to PubChem
16 more reported names
External database identifiers
Advanced structure statistics
- Defined atom stereocentres
- 4
- Undefined atom stereocentres
- 0
- Defined bond stereocentres
- 0
- Undefined bond stereocentres
- 0
- 3D pharmacophore features
- 9
- 3D rings
- 3
- 3D hydrophobes
- 1
- 3D acceptor features
- 3
- 3D donor features
- 1
- 3D anionic centres
- 0
- 3D cationic centres
- 1
- 3D conformers
- 7
- Effective 3D rotors
- 5.2
Machine-readable structure identifiers
- SMILES
COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O- InChI
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1- InChIKey
LOUPRKONTZGTKE-WZBLMQSHSA-N
Evidence from additional scientific databases
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Color/Form: Triboluminescent, orthorhombic needles from absolute alcohol Source: Hazardous Substances Data Bank (HSDB)
- Color/Form: Bulky, white, amorphous powder or crystalline alkaloid Source: Hazardous Substances Data Bank (HSDB)
- Color/Form: CRYSTALS TURN BROWN ON EXPOSURE TO AIR Source: Hazardous Substances Data Bank (HSDB)
- Basic pKa: 8.56 Source: ChEMBL
- Basic pKa: 8.55 Source: ChEMBL
- Dissociation Constants: pK1 (18 °C) = 5.07; pK2 = 9.7 Source: Hazardous Substances Data Bank (HSDB)
- LogP: 3.44 Source: DrugBank
- LogP: log Kow = 3.44 Source: Hazardous Substances Data Bank (HSDB)
- LogP: 2.6 Source: Human Metabolome Database (HMDB)
- Melting Point: 57 °C Source: DrugBank
- Melting Point: 177 °C (some decomposition) Source: Hazardous Substances Data Bank (HSDB)
- Melting Point: Microcrystalline powder; mp: 57 °C; efflorescent; loses one water molecule in air, two water molecules over sulfuric acid; anhydrous at 125 °C /Quinine trihydrate/ Source: Hazardous Substances Data Bank (HSDB)
- Melting Point: 57 °C Source: Human Metabolome Database (HMDB)
- Odor: ODORLESS Source: Hazardous Substances Data Bank (HSDB)
- Physical Description: Solid Source: Human Metabolome Database (HMDB)
- Refractive Index: INDEX OF REFRACTION: 1.625 Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 500 mg/L (at 15 °C) Source: DrugBank
- Solubility: In water, 500 mg/L at 15 °C Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 1 g dissolves in: 1900 mL water, 760 mL boiling water Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 1 g dissolves in: 80 mL benzene (18 mL at 50 °C), 1.2 mL chloroform, 250 mL dry ether, 20 mL glycerol, 0.8 mL alcohol, 1900 mL of 10% ammonia water; almost insoluble in petroleum ether Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Soluble in ether, chloroform, carbon disulfide, glycerol, alkalies, and acids (with formation of salts) Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Sol in pyrimidine Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 3.34e-01 g/L Source: Human Metabolome Database (HMDB)
- pH: pH of saturated aqueous solution = 8.8 Source: Hazardous Substances Data Bank (HSDB)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). Source: Toxin and Toxin Target Database (T3DB)
- Exposure Routes: Oral Source: Toxin and Toxin Target Database (T3DB)
- Signal: Danger Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H302 (22.9%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (28.4%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (99.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (28.4%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334 (83.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 201 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- Signal: Warning Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin] Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- Signal: Danger Source: Hazardous Substances Data Bank (HSDB)
- GHS Hazard Statements: H315: Causes skin irritation [Warning Skin corrosion/irritation]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin]; H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: Hazardous Substances Data Bank (HSDB)
- Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) Source: Hazardous Substances Data Bank (HSDB)
- Health Effects: It is usual for quinine in therapeutic doses to cause cinchonism; in rare cases, it may even cause death (usually by pulmonary edema). Quinine can worsen hemoglobinuria, myasthenia gravis and optic neuritis. It can cause paralysis if accidentally injected into a nerve, and is extremely toxic in overdose[Wikipedia] Source: Toxin and Toxin Target Database (T3DB)
- Toxicity Summary: IDENTIFICATION AND USE: Quinine is a bulky, white, amorphous powder or crystalline alkaloid, used as medication: non-narcotic analgesics; antimalarial; central muscle relaxants. It is also used as flavor in carbonated beverages. HUMAN EXPOSURE AND TOXICITY: Serious hypersensitivity reactions, including anaphylactic shock, anaphylactoid reactions, urticaria, serious skin rashes, angioedema, facial edema, bronchospasm, and pruritus, have been reported with quinine. In addition, thrombocytopenia, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), immune thrombocytopenic purpura, blackwater fever, disseminated intravascular coagulation, leukopenia, neutropenia, granulomatous hepatitis, and acute interstitial nephritis have been reported and may also be due to hypersensitivity reactions to the drug. Potentially fatal cardiac arrhythmias, including torsades de pointes and ventricular fibrillation, have been reported rarely during quinine therapy. At least 1 case of fatal ventricular arrhythmia has been reported in a geriatric patient with preexisting prolonged QT interval treated with IV quinine sulfate for Plasmodium falciparum malaria. Visual impairment can range Source: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: The theorized mechanism of action for quinine and related anti-malarial drugs is that these drugs are toxic to the malaria parasite. Specifically, the drugs interfere with the parasite's ability to break down and digest hemoglobin. Consequently, the parasite starves and/or builds up toxic levels of partially degraded hemoglobin in itself. Source: Toxin and Toxin Target Database (T3DB)
- Uses: Medicine (antimalarial) as the alkaloid or as numerous salts and derivatives; flavoring in carbonated beverages Source: Hazardous Substances Data Bank (HSDB)
- Uses: Flavor in carbonated beverages. Source: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION Source: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION (VET) Source: Hazardous Substances Data Bank (HSDB)
- Uses: For more Uses (Complete) data for QUININE (8 total), please visit the HSDB record page. Source: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >5000; Use (kg) in USA (2002): 56800; Consumption (g per capita; approx.) in Germany (2009): 0.0611; Consumption (g per capita) in the USA (2002): 0.201; Calculated removal (%): 41.8 Source: NORMAN Suspect List Exchange
- Uses: For the treatment of malaria and leg cramps. Used as an antipyretic (fever-reducing), antimalarial, analgesic (painkilling), and anti-inflammatory. It is also used as a flavor component of tonic water and bitter lemon. Source: Toxin and Toxin Target Database (T3DB)
Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record
Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.
Additional source coverage and match status
| Source | Result | Checked |
|---|---|---|
| NIH PubChem PUG-View | Exact match | 2026-08-31 |
A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.
Official source and provenance
- Registered source
- New Zealand cosmetic product schedules 4–8
- Source reference
- Schedule 5, reference 21, source row 40
- Source record ID
S5-40- Source version
- effective-2026-01-01
- Source language
- English
- Translation status
- Original is English
- Effective date
- 2026-01-01
- Source updated
- 2024-01-01
- Snapshot checked
- 2026-08-30 04:54 UTC
- Validation method
- openpyxl extraction; reviewed per-schedule counts
- SHA-256
4e62e372fb0aad7ac630af8c41fa50b38b52a793fd51b99697a65f8ecce1ae8a
Registered dataset notes
- Dataset coverage
- Prohibited and restricted substances, permitted colorants, preservatives and UV filters
- Authority note
- Official EPA group standard schedules; current market-specific rule source
How this record fits the market dataset
Status distribution
Condition text is present on 747 of 2913 current records. An empty condition field is interpreted according to the record type above; it is never converted into an unrestricted-use claim.
New Zealand market context
Complete schedules dataset
Coverage version: Cosmetic Products Group Standard schedules effective 1 January 2026
Schedules 4–8: prohibited, restricted, colourant, preservative and UV-filter entries.
Verification checklist
- Search exact identity across Schedules 4–8.
- Apply use, concentration and warning conditions.
- Check hazardous-substance classification and Group Standard scope.
- Confirm the latest legal instrument, not only the spreadsheet.
Official market sources
- New Zealand cosmetic product schedules 4–8Official EPA group standard schedules; current market-specific rule source
Verification workflow and record completeness
Before using this result in a compliance decision
- Confirm that “Quinine (cinchonan-9-ol, 6'-methoxy-, (8alpha, 9R)-) and its salts” and every CAS/EC identifier refer to the material in your supplier specification.
- Search exact identity across Schedules 4–8.
- Apply use, concentration and warning conditions.
- Check hazardous-substance classification and Group Standard scope.
- Confirm the latest legal instrument, not only the spreadsheet.
- Document the source version and recheck the regulator before manufacture, notification or market placement.
Fields available in this record
- Official substance nameAvailable
- CASAvailable
- ECAvailable
- Separate condition textAvailable
- Effective dateAvailable
- Snapshot hash and methodAvailable
Questions this page answers
Stable citation
Quinine (cinchonan-9-ol, 6'-methoxy-, (8alpha, 9R)-) and its salts. Schedule 5, reference 21, source row 40. New Zealand. Source version effective-2026-01-01. CosIng Checker regulatory record: https://cosingchecker.com/regulations/nz/records/8884/
Cite the regulator as the legal authority. This page is a structured evidence index and verification aid, not a substitute for the official text or professional legal assessment.
Interpretation and limits for New Zealand
This substance is not unrestricted: cosmetic use is subject to the conditions in the cited official record.
Check product type, body area, concentration, purity and warning requirements before deciding whether a formulation is compliant.
How to interpret the legal role
The cited row forms part of a binding rule or legally incorporated list for this market.
Evidence on this page
- Recorded outcome: Restricted
- Legal role: Binding rule
- Source version: effective-2026-01-01
- Effective date: 2026-01-01
What it does not prove
The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.
Further authoritative substance research
These sources can add identity, safety, exposure or hazard context. A link is not evidence that the database contains this exact substance, and none of these sources overrides the market decision above.
Cosmetic Ingredient Review safety assessments
Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents
Independent expert review considered by FDA; not a government approval or binding market rule
Research this identity at the sourceFDA Global Substance Registration System
UNII identifiers, preferred names, substance types, codes and public substance relationships
Identity registry only; UNII availability does not imply FDA review or approval
Research this identity at the sourceILO/WHO International Chemical Safety Cards
Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals
International occupational chemical-safety reference; not cosmetic-use approval
Research this identity at the sourceJapan NITE-CHRIP
Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information
Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules
Research this identity at the sourceNIOSH Pocket Guide to Chemical Hazards
REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals
US occupational-health guidance and limits; not a cosmetic ingredient decision
Research this identity at the sourceOECD eChemPortal
Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records
Discovery gateway; each linked authority remains responsible for its data
Research this identity at the sourceUS EPA CompTox CTX APIs
API key required for importDTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data
Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality
Research this identity at the source